Worthing, United Kingdom

Time filter

Source Type

Kramer M.F.,Bencard Allergie GmbH | Heath M.D.,Allergy Therapeutics
Vaccine | Year: 2014

We are living in an "aluminium age" with increasing bioavailability of the metal for approximately 125 years, contributing significantly to the aluminium body burden of humans. Over the course of life, aluminium accumulates and is stored predominantly in the lungs, bones, liver, kidneys and brain. The toxicity of aluminium in humans is briefly summarised, highlighting links and possible causal relationships between a high aluminium body burden and a number of neurological disorders and disease states.Aluminium salts have been used as depot-adjuvants successfully in essential prophylactic vaccinations for almost 100 years, with a convincing positive benefit-risk assessment which remains unchanged.However, allergen-specific immunotherapy commonly consists of administering a long-course programme of subcutaneous injections using preparations of relevant allergens. Regulatory authorities currently set aluminium limits for vaccines per dose, rather than per treatment course. Unlike prophylactic vaccinations, numerous injections with higher proportions of aluminium-adjuvant per injection are applied in subcutaneous immunotherapy (SCIT) and will significantly contribute to a higher cumulative life dose of aluminium. While the human body may cope robustly with a daily aluminium overload from the environment, regulatory cumulative threshold values in immunotherapy need further addressing. Based on the current literature, predisposing an individual to an unusually high level of aluminium, such as through subcutaneous immunotherapy, has the potential to form focal accumulations in the body with the propensity to exert forms of toxicity. Particularly in relation to longer-term health effects, the safety of aluminium adjuvants in immunotherapy remains unchallenged by health authorities - evoking the need for more consideration, guidance, andtransparency on what is known and not known about its safety in long-course therapy and what measures can be taken to prevent or minimise its risks. The possibility of providing an effective means of measuring aluminium accumulation in patients undergoing long-term SCIT treatment as well as reducing their aluminium body burden is discussed. © 2014 The Authors.


News Article | November 10, 2016
Site: marketersmedia.com

— The report provides comprehensive information on the therapeutics under development for Grass Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Scope - The report provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy - The report reviews pipeline therapeutics for Grass Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Grass Pollen Allergy therapeutics and enlists all their major and minor projects - The report assesses Grass Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Grass Pollen Allergy Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Grass Pollen Allergy Overview 7 Therapeutics Development 8 Pipeline Products for Grass Pollen Allergy - Overview 8 Grass Pollen Allergy - Therapeutics under Development by Companies 9 Grass Pollen Allergy - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Grass Pollen Allergy - Products under Development by Companies 13 Grass Pollen Allergy - Companies Involved in Therapeutics Development 14 ALK-Abello A/S 14 Allergy Therapeutics Plc 15 Anergis SA 16 Biomay AG 17 Circassia Pharmaceuticals Plc 18 HAL Allergy BV 19 Roxall Medizin GmbH 20 Shionogi & Co., Ltd. 21 Grass Pollen Allergy - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 AllerG - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Allergen for Grass Allergy - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 asapiprant - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 BM-32 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 clustoid wiesenlieschgras - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Pollinex Quattro Grass - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Grass Pollen Allergy - Recent Pipeline Updates 43 Grass Pollen Allergy - Dormant Projects 50 Grass Pollen Allergy - Product Development Milestones 51 Featured News & Press Releases 51 Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL 51 For more information, please visit http://www.wiseguyreports.com


News Article | November 30, 2016
Site: www.newsmaker.com.au

The report titled “Global Allergy Immunotherapy Market: Size, Trends & Forecasts (2016-2020)”, provides an in-depth analysis of the global allergy immunotherapy market by value, by methods of administration, by region, etc. The report provides a regional analysis of the allergy immunotherapy market, including the following regions: the US, Europe and Rest of the World. Complete report available at http://www.marketreportsonline.com/540890.html. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global allergy immunotherapy market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The key players of the allergy immunotherapy market ALK-Abello, Allergy Therapeutics, Merck Group and Stallergenes, who are also profiled with their financial information and respective business strategies. Allergy refers to a condition in which the immune system abnormally reacts to the foreign substance. The foreign substance could be in the form of particular food, pollen, pets, metals, fur, dust, etc. to which the body becomes hypersensitive when comes into contact. The foreign substance that triggers the hypersensitive response in the body is known as an allergen. Generally, most substances that cause allergies are normally harmless to the human body and have no effect on the vast majority of people that are not allergic. Allergy is not a disease, it is a mere over-reaction of body to the foreign substance that is not harmful. To diagnose an allergy skin test, blood test and allergy component tests are undertaken. Allergies are generally seasonal and perennial in nature. Purchase a copy of this “Allergy Immunotherapy Market” research reports at http://www.marketreportsonline.com/contacts/purchase.php?name=540890. The global allergy immunotherapy market has increased at a significant CAGR during the years 2009-2015 and projections are made that the market would rise in the next four years i.e. 2016-2020 tremendously. The allergy immunotherapy market is expected to increase due to growth in healthcare expenditure, rising incidence of chronic diseases and increasing global pollution, etc. Yet the market faces some challenges such as, lack of treatment awareness, lack of investor confidence, anaphylaxia, huge treatment costs, etc. Other Related Reports from Pharmaceuticals Market Research Reports at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html. About Us: MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.


— Complete report on Allergy Immunotherapy market spread across 85 pages providing 4 company profiles and 6 tables and 38 figures is now available at http://www.marketreportsonline.com/540890.html. The report titled “Global Allergy Immunotherapy Market: Size, Trends & Forecasts (2016-2020)”, provides an in-depth analysis of the global allergy immunotherapy market by value, by methods of administration, by region, etc. The report provides a regional analysis of the allergy immunotherapy market, including the following regions: the US, Europe and Rest of the World. Complete report available at http://www.marketreportsonline.com/540890.html. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global allergy immunotherapy market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The key players of the allergy immunotherapy market ALK-Abello, Allergy Therapeutics, Merck Group and Stallergenes, who are also profiled with their financial information and respective business strategies. Country Coverage • Europe • Rest of the World • US Allergy refers to a condition in which the immune system abnormally reacts to the foreign substance. The foreign substance could be in the form of particular food, pollen, pets, metals, fur, dust, etc. to which the body becomes hypersensitive when comes into contact. The foreign substance that triggers the hypersensitive response in the body is known as an allergen. Generally, most substances that cause allergies are normally harmless to the human body and have no effect on the vast majority of people that are not allergic. Allergy is not a disease, it is a mere over-reaction of body to the foreign substance that is not harmful. To diagnose an allergy skin test, blood test and allergy component tests are undertaken. Allergies are generally seasonal and perennial in nature. Purchase a copy of this “Allergy Immunotherapy Market” research reports at http://www.marketreportsonline.com/contacts/purchase.php?name=540890. The global allergy immunotherapy market has increased at a significant CAGR during the years 2009-2015 and projections are made that the market would rise in the next four years i.e. 2016-2020 tremendously. The allergy immunotherapy market is expected to increase due to growth in healthcare expenditure, rising incidence of chronic diseases and increasing global pollution, etc. Yet the market faces some challenges such as, lack of treatment awareness, lack of investor confidence, anaphylaxia, huge treatment costs, etc. Few Points from List of Figures: Figure 1: Mechanism of Allergy Figure 2: Diagnosis of Allergy Figure 3: Nature of Allergy Figure 4: Types of Allergy Figure 5: Types of Allergens Figure 6: Types of Immunotherapy Figure 7: Immunotherapy by Methods of Administration Figure 8: Global Allergy Immunotherapy Market by Value; 2009-2015 (US$ Billion) Figure 9: Global Allergy Immunotherapy Market by Value; 2016-2020 (US$ Billion) Figure 10: Global Allergy Immunotherapy Market by Geography; 2015 (Percentage, %) Figure 11: Global Allergy Immunotherapy Market by Method of Administration; 2015 (Percentage, %) Figure 12: Global Subcutaneous Immunotherapy Market by Value; 2009-2015 (US$ Million) Figure 13: Global Subcutaneous Immunotherapy Market by Value; 2016-2020 (US$ Million) Figure 14: Global Sublingual Immunotherapy Solution Market by Value; 2009-2015 (US$ Million) Figure 15: Global Sublingual Immunotherapy Solution Market by Value; 2016-2020 (US$ Million) Other Related Reports from Pharmaceuticals Market Research Reports at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html. For more information, please visit http://www.marketreportsonline.com/540890.html


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Allergy Immunotherapy Market: Size, Trends & Forecasts (2016-2020)" report to their offering. Global Allergy Immunotherapy Market: Size, Trends & Forecasts (2016-2020), provides an in-depth analysis of the global allergy immunotherapy market by value, by methods of administration, by region, etc. The report provides a regional analysis of the allergy immunotherapy market, including the following regions: the US, Europe and Rest of the World. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global allergy immunotherapy market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Allergy refers to a condition in which the immune system abnormally reacts to the foreign substance. The foreign substance could be in the form of particular food, pollen, pets, metals, fur, dust, etc. to which the body becomes hypersensitive when comes into contact. The foreign substance that triggers the hypersensitive response in the body is known as an allergen. Generally, most substances that cause allergies are normally harmless to the human body and have no effect on the vast majority of people that are not allergic. Allergy is not a disease, it is a mere over-reaction of body to the foreign substance that is not harmful. To diagnose an allergy skin test, blood test and allergy component tests are undertaken. Allergies are generally seasonal and perennial in nature. The global allergy immunotherapy market has increased at a significant CAGR during the years 2009-2015 and projections are made that the market would rise in the next four years i.e. 2016-2020 tremendously. The allergy immunotherapy market is expected to increase due to growth in healthcare expenditure, rising incidence of chronic diseases and increasing global pollution, etc. Yet the market faces some challenges such as, lack of treatment awareness, lack of investor confidence, anaphylaxia, huge treatment costs, etc. The key players of the allergy immunotherapy market ALK-Abello, Allergy Therapeutics, Merck Group and Stallergenes, who are also profiled with their financial information and respective business strategies. For more information about this report visit http://www.researchandmarkets.com/research/khp5ht/global_allergy


CTA approval in Spain for Phase I AM101 clinical study evaluating safety of adjuvanted, modified house dust mite allergy vaccine CTA approval in Spain for Phase I AM101 clinical study evaluating safety of adjuvanted, modified house dust mite allergy vaccine Allergy Therapeutics ( : AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces that the Phase I clinical study investigating the safety and tolerability of Acarovac MPL (monophosphoryl lipid A) has received Clinical Trial Application (CTA) approval in Spain. House dust mites are a major cause of perennial allergic rhinitis and allergic asthma1. Acarovac MPL builds on the strong foundation of technologies employed in the successful Pollinex® Quattro range of subcutaneous allergy immunotherapies, and builds on the demonstrated efficacy2 of the existing successful product platform of Acarovac Plus™, the fastest growing "named-patient product" in Allergy Therapeutics' Spanish subsidiary. Acarovac MPL is the only house-dust mite immunotherapy in development utilising MCT® (microcrystalline tyrosine), a natural, biodegradable depot, and the adjuvant MPL for the treatment of perennial allergic rhinitis making this vaccine unique in a $1.5 billion per annum market3. CTA approval has been granted and the Company now expects this formulation to begin Phase I studies immediately, to assess the safety and tolerability of two different dose regimens. Both treatment regimens include a two-to-four week initial up-dosing phase but differ in the duration of the later maintenance phase. The Phase I trial of 32 patients is expected to last one year, and to be delivered on-time in-line with the Company's stated strategic plan when funding the programme in November 2015. If the Phase I trial is successful, the Company expects to launch Acarovac MPL in Spain on a named-patient basis. Commenting on the CTA approval, Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, said: "By using the successful biodegradable adjuvant system of MCT® and MPL, integral in our seasonal marketed vaccines, in a perennial house dust mite vaccine, we aim to improve both safety and efficacy for the thousands of patients who suffer year-round due to house dust mite allergy. Acarovac Quattro will provide convenience to our patients and doctors and more efficient pharmacoeconomics. Effectively, the dosing regime in Acarovac Quattro has the potential to improve the convenience, adherence and compliance that is essential for a successful treatment, and builds on the acceptance of the existing Acarovac Plus platform." About Allergy Therapeutics Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.495 employees and is listed on the London Stock Exchange ( : AGY). For more information, please see www.allergytherapeutics.com. References 1. Calderón M et al., Respiratory allergy caused by house dust mites: What do we really know? J Allergy Clin Immunol. 2015 Jul;136(1):38-48 2. Roger, A., Depreux, N., Jurgens Y., Heath M, Garcia G., Skinner M, A novel and well tolerated mite allergoid subcutaneous immunotherapy: Evidence of clinical and immunologic efficacy. Immunity, Inflammation and Disease, 2014; 2 (2); 92-98 3. QYR Pharma report. September 2016 This information is provided by RNS The company news service from the London Stock Exchange


Patent
Allergy Therapeutics and Corixa Corporation | Date: 2011-05-18

A method of producing a mucosal and systemic immune response in a mammal comprising administering sublingually effective amount of a composition comprising at least one antigen and a glycolipid adjuvant to said mammal.


Patent
Allergy Therapeutics | Date: 2012-04-20

A method of preparing a composition comprising one or more antigens adsorbed to an amino acid wherein said method comprises: (i) mixing a solution of one or more antigens with a solution of the amino acid in an aqueous acid whilst neutralising the mixture of solutions, thereby forming an adsorbate comprising the one or more antigens and the amino acid; (ii) separating the adsorbate into a desired buffer by cross-flow filtration thereby forming said composition; and (iii) recovering said composition; wherein steps (i) to (iii) are performed in a sterile environment and within a closed system.


News Article | March 12, 2015
Site: www.fiercebiotech.com

Allergy Therapeutics (AIM:AGY) has turned to public investors for £20 million ($30 million) to move its subcutaneous immunotherapy allergy vaccine through late-phase development. The cash will fund Allergy Therapeutics' attempt to bounce back from the 5-year clinical hold of its U.S. trial program. The FDA initiated the clinical hold on Pollinex Quattro Grass in 2007 after a trial participant reported numbness and weakness. At the time, the regulator was particularly concerned about the side effects of novel adjuvants and took until 2012 to lift the hold. Worthing, United Kingdom-based Allergy Therapeutics had hoped getting the regulatory green light would enable it to snag a partner to commercialize the vaccine in the U.S., but three years later it is still flying solo. Now, with the FDA reviewing Allergy Therapeutics' protocol and statistical analyses, the U.S. clinical trial program is on the cusp of getting back on track. And despite the delays, Allergy Therapeutics thinks there is still pent up demand for its grass vaccine in the country. "We have the opportunity to be the first FDA-licensed seasonal subcutaneous immunotherapy allergy vaccine, and so access an estimated $2 billion market," Allergy Therapeutics CEO Manuel Llobet said in a statement. To reach that point, Allergy Therapeutics has placed enough shares to net it the £20 million it needs for the clutch of studies requested by the FDA. An environmental exposure chamber Phase III efficacy trial--which puts participants in contact with allergens--and a patient registry study are requirements of the biological licence application. Allergy Therapeutics also plans to run safety and pilot studies to assess the dosing of Pollinex Quattro Grass. If everything goes according to plan, Allergy Therapeutics will begin selling Pollinex Quattro Grass in the U.S. in 2019 and become a financially self sustaining business. Since going public in 2004, Allergy Therapeutics has raised cash through placements several times, one of which saw Chile-based CFR Pharmaceuticals become the majority shareholder. CFR was bought out by Abbott Laboratories ($ABT) last year, making the healthcare giant the controlling shareholder in Allergy Therapeutics. Related Articles: FDA lifts hold on Allergy Therapeutics' grass pollen allergy vax Allergy Therapeutics shares spike on late-stage data Allergy Therapeutics afflicted by FDA's move to halt trials


News Article | November 7, 2016
Site: www.newsmaker.com.au

Latest Cedar Pollen Allergy Pipeline Review, H2 2016, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics. Cedar Pollen Allergy therapeutics industry report provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects. Browse more detail information about Cedar Pollen Allergy market report at: http://www.absolutereports.com/cedar-pollen-allergy-pipeline-review-h2-2016-10393244 The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Key players in Cedar Pollen Allergy – Pipeline Review, H2 2016: Get a PDF Sample of Cedar Pollen Allergy Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10393244 And Others And other drug profiles Have any query? ask our expert @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10393244 Key Topics Covered: 1.Introduction 2.Cedar Pollen Allergy Overview 3.Cedar Pollen Allergy Therapeutics Development 4.Pipeline Products for Cedar Pollen Allergy - Overview 5.Pipeline Products for Cedar Pollen Allergy - Comparative Analysis 6.Cedar Pollen Allergy - Therapeutics under Development by Companies 7.Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes 8.Cedar Pollen Allergy Products Glance 9.Late Stage Products 10.Clinical Stage Products 11.Early Stage Products 12.Cedar Pollen Allergy - Products under Development by Companies 13.Cedar Pollen Allergy - Products under Investigation by Universities/Institutes 14.Cedar Pollen Allergy - Companies Involved in Therapeutics Development 15.Cedar Pollen Allergy Drug Profiles 16.Cedar Pollen Allergy Dormant Projects 17.Cedar Pollen Allergy Discontinued Products 18.Cedar Pollen Allergy Featured News & Press Releases And Continue… Get Discount on Cedar Pollen Allergy Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10393244 This 47 pages research study help to: - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cedar Pollen Allergy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Loading Allergy Therapeutics collaborators
Loading Allergy Therapeutics collaborators